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abstract: The rapid rise in obesity,metabolic syndrome and type 2 diabetes is one of themajor healthcare problems of theWesternworld.
Affected individuals are often treated with statins (3-hydroxy-3-methylglutaryl co-enzyme A [HMGCoA] reductase inhibitors) to reduce circu-
lating cholesterol levels and the risk of developing cardiovascular disease; given the evolving demographic proﬁle of these conditions, such drugs
are increasinglyprescribed towomenof reproductiveage.Wehavepreviously shownthatexposureof placental tissue to statins inhibits the action
of insulin-likegrowth factors (IGF)-I and -IIwhich arekey regulatorsof trophoblastproliferationandplacental development.N-linkedglycans in the
IGF receptor, IGF1R, inﬂuence its presentation at the cell surface. This study aimed to determine whether statins, which are known to affect
N-glycosylation, modulate IGF1R function in placenta. Treatment of ﬁrst trimester villous tissue explants with statins (pravastatin or cerivastatin)
or inhibitors of N-glycosylation (tunicamycin, deoxymannojirimycin or castanospermine) altered receptor distribution in trophoblast and atte-
nuatedproliferation inducedby IGF-I or IGF-II (Ki67; P, 0.05, n ¼ 5).Decreased binding of Phaseolus vulgaris lectin andphytohaemagglutinin to
IGF1R immunoprecipitated from treated explants demonstrated reduced levels of complex N-linked glycans. Co-incubation of tissue explants
with statins and farnesyl pyrophosphate (which increases the supply of dolichol intermediates), prevented statin-mediated disruption of IGF1R
localizationand reversed thenegativeeffecton IGF-mediated trophoblastproliferation.Thesedata suggest that statins attenuate IGFactions in the
placenta by inhibiting N-linked glycosylation and subsequent expression of mature IGF1R at the placental cell surface.
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Introduction
The rapid rise in obesity, metabolic syndrome and type 2 diabetes is one
of the major healthcare problems of the Western world (Wild et al.,
2004; Shaw et al., 2010). Affected individuals are often treated with
3-hydroxy-3-methylglutaryl co-enzymeA (HMGCoA) reductase inhibi-
tors (statins) to reduce circulating cholesterol levels and the risk of devel-
oping cardiovascular disease. Given that the incidence of obesity and
diabetes has risen amongst younger populations (Flegal et al., 1998;
Ogden et al., 2014) and that many women are delaying child bearing
(Heffner, 2004), statins are increasingly prescribed to women of repro-
ductive age.
Studies in rodents suggest that administration of statins may have
beneﬁcial effects in pregnancy complications, such as pre-eclampsia,
that are associated with altered vascular function (Fox et al., 2011;
Kumasawa et al., 2011; Bauer et al., 2013). These ﬁndings have led to a
surge in the number of studies investigating the use of statins in human
pregnancy and two randomized control trials are underway (ISRCTN,
2009; Costantine and Cleary, 2013). However, statins can affect placen-
tal development (Kenis et al., 2005; Tartakover-Matalon et al., 2007;
Forbes et al., 2008a; Odiari et al., 2012) and cross the placental barrier
to target the developing fetus, so their use in pregnancy is still contrain-
dicated (Godfrey et al., 2012; Lecarpentier et al., 2012;Winterfeld et al.,
2013). Nonetheless, given that 50% of pregnancies are unplanned
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(Finer and Henshaw, 2006), it is likely that in the coming years, inadvert-
ently or otherwise, many pregnant women and their fetuses will be
exposed to statins.
In normal placental development, cytotrophoblast progenitor cells
proliferate and differentiate into one of two subtypes; syncytiotropho-
blast, which is in direct contact with maternal blood and responsible
for nutrient and gas exchange (Aplin, 2010); or extravillous trophoblast
which migrate into the maternal uterine decidua and myometrium
(Aplin, 1991). The syncytium is terminally differentiated, thus growth
and thenmaintenance of the syncytial surface area occur via the continu-
ousproliferation, differentiation and fusionof underlying cytotrophoblast
cells (reviewed in Aplin, 2000). Altered rates of cytotrophoblast prolif-
eration are associated with different pathologies; enhanced levels are
associated with increased fetal growth (macrosomia) whilst low levels
are linked to reduced (FGR) fetal growth (Jansson and Powell, 2006).
The insulin-like growth factor (IGF) axis is an important regulator of
placental cell turnover and fetal growth (Forbes and Westwood,
2008). IGF-I and -II exert their actions in the placenta by binding to the
type-1 IGF receptor (IGF1R) in trophoblast, activating the MAPK and
PI3K pathways and initiating a cascade of phosphorylation events to
promote mitogenesis and protect against apoptosis (Forbes et al.,
2008b). Altered IGF signalling results in aberrant placental growth
(Walenkamp et al., 2006; Kruis et al., 2010). We have reported that
treatment of ﬁrst trimester human placental tissue with statins (pravas-
tatin or cerivastatin) decreases IGF-mediated proliferation (Forbes
et al., 2008a). The actions of statins arenot limited tomodulation of chol-
esterol levels; theycausedepletionofmevalonate, andconsequently, far-
nesyl pyrophosphate, resulting in reduced levels of dolichol phosphate,
an essential cofactor for proteinN-linked glycosylation. Co-translational
N-glycosylation inﬂuencesprotein folding and its inhibition can lead to ca-
tabolism of unfolded proteins and depletion of functional proteins from
their sites of action, including the cell surface. IGF1R contains several
N-glycans (Siddals et al., 2004, 2011), and inhibition of N-glycosylation
alters cell surface abundance and blocks IGF action in tumour cells
(Contessa et al., 2008) and vascular smooth muscle cells (Siddals et al.,
2011). Plant lectins, carbohydrate-binding proteins with a range of
sugar speciﬁcities that include various types of N-linked oligosaccharide,
have been used extensively in histochemical studies to delineate the di-
versity of glycans at the maternal– fetal interface (Jones et al., 2007),
and introduce the hypothesis of a ‘glycocode’ that deﬁnes interfacial
characteristics and inﬂuences cellular interactions (Jones and Aplin,
2009; Aplin and Jones, 2012). This study explored the hypothesis that
statins attenuate IGF-induced proliferation in the placenta by altering
N-glycosylation and cell surface expression of IGF1R.
Materials andMethods
Materials
HMG-CoA reductase inhibitors were a kind gift of Bayer Pharmaceuticals
PLC and AstraZeneca PLC. Deoxymannojirimycin and tunicamycin were
purchased from Calbiochem. Farnesyl pyrophosphate and castanospermine
were purchased from Sigma.
Tissue culture
Late ﬁrst trimester (8–12 week) human placental tissue was collected with
maternal informed consent and approval from our Local Research Ethics
Committee following elective surgical or medical termination of pregnancy.
Tissuewas transferred into a 1:1mixture of serum-freeDulbecco’sModiﬁed
Eagle’s Medium (DMEM) and Ham’s F12 (F12) containing 100-units/ml
penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine (DMEM/F12),
dissected into 5 mm3 pieces under sterile conditions and immediately used
in the experiments described below.
HMG-CoA reductase inhibitor and
glycosylation inhibitor treatments
Tissue (n ¼ 5) was pre-incubated with cerivastatin (50 mnM), pravastatin
(250 mnM)or the glycosylation inhibitors: tunicamycin (1 mg/ml; an inhibitor
of N-acetylglucosamine transferase which prevents formation of dolichyl
pyrophospho-N-acetylglucosamine, blocking N-glycosylation of newly
synthesized proteins (McDowell and Schwarz, 1988)), castanospermine
(5 mg/ml; a glucosidase inhibitor that prevents exit of nascent glycoprotein
from the ER) or deoxymannojirimycin (DMJ, 0.5 mM; a mannosidase inhibi-
tor, which prevents the conversion of high mannose type to complex type
oligosaccharides (Fuhrmann et al., 1984)), in DMEM/F12 for 24 h. IGF-I
(10 mnM) or IGF-II (10 mnM) was then added and explants were cultured
for a further 24 h. In some experiments (n ¼ 5), 20 mM farnesyl pyrophos-
phate (FPP)—a concentration that we have previously shown reverses the
effect of cerivastatin in 3T3L1 cells (Siddals et al., 2004)—was added to
explants at the same time as HMG-CoA reductase inhibitors.
Immunohistochemistry
Following exposure to inhibitors and/or IGF, placental tissue was ﬁxed in
4 w/v % paraformaldehyde overnight, embedded in parafﬁn wax and sec-
tioned (5 mM). Sectionswere boiled in 0.1 mMsodiumcitrate buffer tomaxi-
mize antigen retrieval and then incubated with rabbit anti-IGF1Rb (1:100;
Biosource, UK), mouse anti-Ki67 (MIB-1 clone, 1:200; DakoCytomation
Ltd, Cambridgeshire, UK), non-immune rabbit IgG (Sigma, UK) or non-
immune mouse IgG (DakoCytomation Ltd, Cambridgeshire, UK) followed
by biotinylated swine anti-rabbit IgG antibody or biotinylated goat anti-
mouse IgG (1:200; DakoCytomation Ltd, Cambridgeshire, UK). Staining
was visualized using the avidin-peroxidase method with haematoxylin coun-
terstain as previously described (Forbes et al., 2008b) and images were cap-
tured using a Leica microscope. Levels of cytotrophoblast proliferation were
then determined as previously described (Forbes et al., 2008b) and
expressed as a percentage of total cytotrophoblast number. Comparisons
between groups were made using the Kruskal–Wallis test followed by a
Dunn’s post hoc test. Data were considered signiﬁcant at P, 0.05.
Western blotting
IGF receptor processing was assessed by immunoblotting. Lysates of whole
placental tissuewereprepared inRIPAbuffer as previously described (Forbes
et al., 2009). One hundred mg protein from each sample was resolved by
SDS–PAGE and transferred to nitrocellulose membranes for western blot-
ting with antiserum speciﬁc for IGF1Rb (rabbit polyclonal; 1:500; Santa
Cruz Biotechnology, Inc., CA, USA). Immune complexes were visualized
by probing with HRP-anti-rabbit-IgG followed by enhanced chemilumines-
cence (ECL).
Analysis of IGF1R glycosylation
Immunoprecipitation of IGF1R
Lysatesof placental explants treatedwithHMGco-reductaseor glycosylation
inhibitors (n ¼ 3) were pre-cleared with protein-G-Sepharose, then incu-
bated with anti-IGF1Rb antibody (mouse monoclonal IgG, Santa Cruz
Biotechnology) and protein-G-Sepharose overnight at 48C. The immune
complexes were pelleted by centrifugation, washed three times with
ice-cold phosphate-buffered saline and then resuspended in reducing SDS
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loading buffer (0.125 M Tris HCl, pH 6.8, 2 w/v % SDS, 10 v/v % glycerol,
5 v/v % 2-mercaptoethanol, 0.25 v/v % bromphenol blue). IGF1R enrich-
ment was conﬁrmed by western blot analysis of immunoprecipitates as
described above.
Lectin dot blots
IGF1Rglycosylation statuswasdeterminedbydotblot using amodiﬁcation to
a previously published method (Schumacher et al., 1992) and two lectins,
with different sugar speciﬁcities (Table I), that have previously been shown
to recognize IGF1R (Masnikosa et al., 2006). Brieﬂy, 10 mg of each sample
(n ¼ 3) was applied to nitrocellulose membranes. Membranes were dried
at room temperature for 15 min and non-speciﬁc binding sites blocked
by soaking in 5 w/v % BSA for 30 min at room temperature. Membranes
were incubated with biotin-labelled lectins: Phaseolus vulgaris lectin
(ePHA) or l-phytohaemagglutinin (lPHA) (10 mg/ml in 0.1 M Tris-buffered
saline (TBS)) for 1 h at room temperature, and then washed three times
Figure1 Glycosylation inhibitors attenuate insulin-like growth factor (IGF)-inducedproliferation. Explants of humanﬁrst trimester placenta (n ¼ 5)were
incubated in the absence or presence of tunicamycin (TM; 1 mg/ml), castanospermine (CS; 5 mg/ml) or deoxymannojirimycin (DMJ; 0.5 mM) for 24 h
before the addition of vehicle, IGF-I (10 nM) or IGF-II (10 nM) and culture for a further 24 h. Proliferation was assessed by using immunohistochemistry
(A) to determine the number of Ki67-positive cytotrophoblast as a percentage of total cytotrophoblast and data are presented (B) as median and
range of ﬁve independent experiments. a: ,0.05 versus control untreated, b: ,0.05 versus IGF-I alone, c: ,0.05 versus IGF-II alone.
.............................................................................................................................................................................................
Table I Lectins used for dot blots.
Lectin Abbreviation Gylcosylation sites detected
Phaseolus vulgaris
lectin
E-PHA Bisected complex-type N-glycans; does not bind any known glycolipid or O-glycan (Jones et al., 2008)
Phytohaemagglutinin L-PHA Certain branched, complex-type N-glycans containing the pentasaccharide sequence
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-6)Mana1-R.
Does not bind to any known glycolipid or O-glycan. (Jones et al., 2008)
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(10 min in TBS containing 0.2 v/v % Tween 20) before incubation with
HRP-conjugated streptavidin (1:2000; Cell Signaling Technologies, UK) for
1 h. Binding was visualized by ECL and intensity of dots quantiﬁed by densi-
tometry using Image J software.
Results
Glycosylation inhibitors attenuate
IGF-induced proliferation in a manner
similar to HMG-CoA reductase inhibitors
The importance of IGF1R glycosylation for IGF-induced cytotrophoblast
proliferation was investigated by examining the effect of treatment with
inhibitors of N-linked glycosylation. First trimester placental explants
were pre-treated with inhibitor for 24 h before exposure to IGF-I
(10 nM) or IGF-II (10 nM) for a further 24 h. Each of the inhibitors atte-
nuated IGF-stimulated trophoblast proliferation by at least 6-fold (Fig. 1).
This degreeof reduction in IGF-induced proliferationwas comparable to
the effect observed following treatment with HMG-CoA reductase inhi-
bitors (at least 3-fold; see Fig. 4 and datawithin Forbes et al., 2008b) sug-
gesting that the ability of statins to attenuate IGF-actions in the ﬁrst
trimester placentamaybe a consequence of altered IGF1R glycosylation.
Placental IGF1R glycosylation and cell surface
localization are altered by HMG-CoA
reductase inhibitors in the ﬁrst trimester
human placenta
The effects of pravastatin, cerivastatin and the three inhibitors of glyco-
sylation on the glycosylation of placental IGF1Rwere examined by asses-
sing the binding of two lectins that recognizeN-linked glycans: Phaseolus
vulgaris lectin (ePHA) and l-phytohaemagglutinin (lPHA). Lysates from
placental explants were enriched for IGF1R by immunoprecipitation
(Fig. 2A) then analysed by lectin dot blot (Fig. 2B). The observation of
dots was speciﬁcally dependent on lectin binding as signal was absent
from membranes probed with streptavidin-HRP alone. Untreated lysates
showed binding of both lectins, whereas in samples from explants that
had been exposed to cerivastatin or pravastatin, reduced binding of ePHA
and lPHAwasobserved. Similarly, thebinding of ePHAand lPHAwasmark-
edly reduced in lysates from placentas exposed to glycosylation inhibitors.
IGF1R is present on the microvillous membrane (MVM), but more
prominently in vesicular bodies in the syncytioplasm, especially apically
near the MVM, and in cytotrophoblasts (Fig. 3A). Exposure of explants
topravastatin (250 nM; Fig. 3B) or cerivastatin (50 nM; Fig. 3C) disrupted
IGF1R distribution; overall the staining declined in intensity and reduc-
tions were apparent in the density of stained vesicles in all intracellular
locations. Similar changes in distribution were observed following treat-
ment with the three N-glycosylation inhibitors (Fig. 3D–F).
Supplementation of placental explants with
farnesyl pyrophosphate attenuates the effect
of HMG-CoA reductase inhibitors on IGF1R
localization and IGF-induced cytotrophoblast
proliferation
Our data suggest that it may be possible to prevent the adverse effects
of statins by promoting protein glycosylation. The intermediarymetabol-
ite in the conversion of mevalonate to the dolichol phosphate needed
for subsequent protein glycosylation is farnesyl pyrophosphate; thus
we investigated whether supplementation of placental explants with far-
nesyl pyrophosphate could prevent statin-mediated disruption of IGF1R
cell surface expression and, in turn, IGF-induced proliferation. Figure 4A
shows that farnesyl pyrophosphate (20 mM) added to explants at the
same time as statin can reduce the disruption to IGF1R cell surface dis-
tribution. Moreover, cerivastatin and pravastatin attenuation of IGF-I
(10 nM) and -II (10 nM)-induced cytotrophoblast proliferation was
overcome by co-incubation of explants with farnesyl pyrophosphate
(P, 0.05; Fig. 4B).
Figure 2 Insulin-like growth factor 1 receptor (IGF1R) glycosylation in
the humanplacenta is reducedby3-hydroxy-3-methylglutaryl co-enzyme
A [HMG-CoA] reductase inhibitors. First trimester placental explants
were incubated in the absence or presence of pravastatin (250 nM), cer-
ivastatin (50 nM), tunicamycin (1 mg/ml), castanospermine (5 mg/ml) or
deoxymannojirimycin (DMJ; 0.5 mM) for 24 h. IGF1Rwas immunopreci-
pitated fromthe samplesusing IGF1Rspeciﬁcantibodies (ormouse IgGas
a negative control) (A) and its glycosylation status analysed by lectin dot
blot (B) using lectins that recognize different glycosylation sites: Phaseolus
vulgaris lectin (ePHA) and l-phytohaemagglutinin (lPHA). Both statin
treatment and glycosylation inhibitors reduced the levels of IGF1R glyco-
sylation detected by both ePHA and lPHA. Human serum was used as a
positive control and speciﬁcityof the detectionmethodwas conﬁrmedby
the absence of positive signal when no lectins were used (streptavidin-
horse radish peroxidase [HRP] only). Each image is representative of
experiments performed on three individual placentas.
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Figure 3 3-Hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors and glycosylation inhibitors alter insulin-like growth factor 1 re-
ceptor (IGF1R) distribution in the human placenta. Explants of terminal villi ﬁrst trimester placenta (dissected from the point shown by the solid line in
the line drawing) were untreated (A) or incubated in the presence of (B) pravastatin (250 nM), (C) cerivastatin (50 nM), (D) tunicamycin (1 mg/ml),
(E) castanospermine (5 mg/ml) or (F) deoxymannojirimycin (0.5 mM) for 24 h. IGF1R localization was analysed by immunohistochemistry using an
IGF1R-speciﬁc antibody. In someexperiments the primary antibodywas replacedby IgG as a negative control (G). The intervillous space (IVS),microvillous
membrane (MVM), basal membrane (BM), syncytiotrophoblast (ST), cytotrophoblast (CT) and villous stroma (VS) are shown in the line drawing and are
indicatedby arrows in images (A–F). IGF1R is localized to theMVM, throughout the STand inCT (A). The expression of IGF1Ron thematernal facingMVM
and CT plasma membrane was disrupted in the presence of either pravastatin (B) or cerivastatin (C). IGF1R expression onMVMwas disrupted by each of
the three glycosylation inhibitors. Deoxymannojirimycin also decreased IGF1R expression at the CT cell surface. Each image is representative of staining
observed in three individual placentas. Scale bars on images represent 50 mM.
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Discussion
Previous work has shown that in human placenta, IGF1R exists as mul-
tiple glycoforms which bear complex-, hybrid- or high mannose-type
N glycans (Masnikosa et al., 2006). In other tissues, glycosylation of
IGF1R, in particular,modiﬁcation ofN913 (Kim et al., 2012), is necessary
for its presentation at the cell surface (Dricu et al., 1999; Girnita et al.,
2000; Itkonen and Mills, 2013) and consequently, its availability for
ligand binding (Girnita et al., 2000; Siddals et al., 2004, 2011). Inhibition
of HMG-CoA reductase by statins (Stancu and Sima, 2001) results in de-
pletion of mevalonate, and downstream of this, a reduction in the supply
of dolichol phosphate needed for N-glycosylation (Carroll et al., 1992);
given these effects on cellularmetabolism,wehypothesized that our pre-
vious ﬁnding of reduced trophoblast proliferation in statin-exposed pla-
cental explants (Forbes et al., 2008a)was caused by a reduction in IGF1R
N-glycosylation. Our current data are consistent with this hypothesis
as the glycosylation, localization and function of IGF1R in placental
explants treated with either cerivastatin or pravastatin were similar to
that observed in tissue cultured with direct inhibitors of glycosylation
(Fig. 5). Moreover, these effects could be circumvented by supplying
explantswith thedolichol phosphateprecursor, farnesyl pyrophosphate.
The reduction in cell surface receptor abundance seen in response to all
treatments is most simply explained by the degradation of misfolded or
glucosylated (immature) precursor blocked from release at the ER. The
turnover time of IGF1R in placenta is not known, but it is reasonable to
speculate that immunoreactive receptor detected after drug exposure
represents the remains of the starting pool. Our ﬁndings are in keeping
with other studies that have investigated the effect of statins on IGF1R
processing and signalling in a variety of normal and transformed cell
lines (Dricu et al., 1997, 1999; Girnita et al., 2000; Sekine et al., 2008;
Figure 4 The effect of 3-Hydroxy-3-methylglutaryl co-enzymeA (HMG-CoA) reductase inhibitors on insulin-like growth factor 1 receptor (IGF1R) cell
surface expression and IGF-induced proliferation can be attenuated by co-incubationwith glycosylation inhibitors. First trimester placental explants (n ¼ 5)
were incubated in the absence or presence of cerivastatin (CV; 50 nM) or pravastatin (PV; 250 nM) alone or in combination with farensyl pyrophosphate
(FPP; 20 mM) for 24 h before the addition of IGF-I (10 nM) or IGF-II (10 nM) and culture for a further 24 h. (A) IGF1R localization was analysed by immu-
nohistochemistry using an IGF1R-speciﬁc antibody. Arrows indicate microvillous membrane (MVM), syncytiotrophoblast (ST), cytotrophoblast (CT) and
villous stroma. Pravastatin and cerivastatin donot disrupt IGF1Rexpression in thepresenceof FPP. Each image is representativeof stainingobserved in three
individual placentas. Scale bars on images represent 50 mM. (B) Proliferation was assessed by using immunohistochemistry to determine the number of
Ki67-positive cytotrophoblast as a percentage of total cytotrophoblast and data are presented as median and range of ﬁve independent experiments.
A Kruskal–Wallis test followed by a Dunn’s post hoc test was used to assess signiﬁcance (P, 0.05; n ¼ 5) a ¼ different from control, untreated tissue;
b ¼ different from IGF-I treated tissue; c ¼ different from tissue treated with pravastatin and IGF-I; d ¼ different from tissue treated with cerivastatin
and IGF-I ; e ¼ different from IGF-II treated tissue; f ¼ different from tissue treated with pravastatin and IGF-II; g ¼ different from tissue treated with
cerivastatin and IGF-II.
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Siddals et al., 2011). In humans, IGF signalling through IGF1R is a key
determinant of cytotrophoblast mitogenesis and placental expansion
(Forbes et al., 2008b). However our previous work (Forbes et al.,
2008b, 2012) suggests that this pathway ismore important formediating
maternally regulated placental growth as cytotrophoblast proliferation
ex vivo seems to be independent of placentally derived IGF. This is con-
sistent with our current data showing that despite causing a decrease
in IGF1R glycosylation, statins do not affect basal proliferation. Work
in our own and other labs suggests that EGFR activity contributes to
the endogenous regulation of trophoblast proliferation (Forbes and
Westwood, 2010; Forbes et al., 2012). EGFR membrane expression,
afﬁnity for ligand, dimerization and intracellular signalling partners are
all affected by N-glycosylation status (Whitson et al., 2005; Contessa
et al., 2008) and there is evidence that statins have a detrimental effect
on its activation and function (Liao et al., 2008; Zhao et al., 2010).
However, deglycosylated EGFR does retain some signalling activity
(Soderquist and Carpenter, 1984; Wang et al., 2001).
Clinical trials are currently testing statins, in particular pravastatin, for
improving placental vascular function in pregnancy complicated by pre-
eclampsia (ISRCTN, 2009; Costantine and Cleary, 2013). In vivo studies
support thenotion that statinsmighthaveapositiveeffectonvascular func-
tion in placenta, aspravastatin treatmentof twodifferentmousemodels of
pre-eclampsia caused an improvement in vascular reactivity (Costantine
et al., 2010), placental vasculogenesis (Cantoni et al., 2011) and blood
ﬂow (Singh et al., 2011). All of these studies administered pravastatin at
embryonicday7.5+which, givenourdataonhumanprimary trophoblast,
would be predicted to affect placental growth. The fact that none of the
studies have reported reduced placental or fetal weightsmay be explained
by inter-species differences in the role of IGF1R. In humans altered IGF1R
expression or function is associated with aberrant placental and fetal
growth (Walenkamp et al., 2006; Kruis et al., 2010) whereas in mice,
the role of IGF1R in the placenta is less clear. The birthweight of both
Igf1 and Igf1r null mice is reduced without changes to placental growth
(Baker et al., 1993). Furthermore, whilst the reduced fetal growth
observed in Igf2 knockout mice can be attributed to aberrant placental
development and function (Baker et al., 1993; Constancia et al., 2002,
2005; Sibley et al., 2004), the ﬁnding that Igf2 and Igf-2/Igf1r double
mutants have an identical placental phenotype suggests that IGF-II does
not signal through IGF1R in the placenta (Baker et al., 1993). Therefore,
in the murine placenta, statin-mediated alteration of IGF1R glycosylation
may not affect trophoblast proliferation.
Further evidence for species-dependent effects of statins in pregnancy
comes from studies investigatingmiscarriage and pre-term labour (PTL).
Both simvastatin and pravastatin prevent fetal loss in a mouse model of
anti-phospholipid syndrome (Girardi, 2009) but pravastatinwas ineffect-
ive in a human trophoblast cell line model of this condition (Odiari et al.,
2012). Similarly, statins protected against PTL induced by lipopolysac-
charide administration (Gonzalez et al., 2014) yet some studies report
that in women, PTL is more frequent in those exposed to statins in
early gestation (Winterfeld et al., 2013).
Figure 5 Schematic representation of the effect of statins/glycosylation inhibitors on insulin-like growth factor 1 receptor (IGF1R) and cytotrophoblast
proliferation. IGF present in the intervillous space (IVS) stimulates the N-glycosylated IGF1R located at the microvillous membrane (MVM) of syncytiotro-
phoblast (ST) and/or cytotrophoblast (CT) plasma membrane to activate intracellular signalling molecules, previously shown to include MAPK (Forbes
et al., 2008b), and promote cytotrophoblast proliferation.Wepropose that statins inhibit the production ofmevalonate and downstreampathways (repre-
sented by dotted arrow) to result in a reduction in the levels of farnesyl pyrophosphate, the precursor of the dolichol phosphate that is needed for
N-glycosylation in the ST (as shown) and in the CT. As a consequence, the glycosylation of IGF1R in the endoplasmic reticulum (ER)/golgi apparatus is
reducedwhich leads to less IGF1R being expressed at theMVM/cytotrophoblast cell surface and abolition of IGF-stimulated cytotrophoblast proliferation.
Glycosylation inhibitors (GI) also affect IGF1R glyco-processing in the ER/golgi apparatus of ST/CT and thus the functional effects of these compounds are
similar to those observed in response to statins.
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Recent studies using the dually perfused human placenta have shown
that pravastatin can cross the placenta (Nanovskaya et al., 2013; Zarek
et al., 2013) and thus it is possible that in addition to indirectly affecting
pregnancy outcome by inﬂuencing placental growth/function, statins
may have a direct effect on fetal development. Indeed, the FDA have
assigned statins to pregnancy category X (Girardi, 2013) although the
latest systematic review and meta-analysis of available data suggest
that they are unlikely to be teratogenic (Kusters et al., 2012). Our data,
and that of others using models of human placenta (Kenis et al., 2005;
Tartakover-Matalon et al., 2007; Odiari et al., 2012), suggest that due to
their effect on early placental development, women should avoid using
statins during the ﬁrst trimester; the outcomes of the trials that are admin-
istering statins at later time points will be useful in exploring their potential
as a therapy for complications manifesting in late pregnancy.
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